XML 49 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net income (loss) per common share (Tables)
9 Months Ended
Sep. 30, 2022
Loss per share  
Schedule of Antidilutive Securities

      Number of  Per share
   Amount  shares  amount
          
Basic earnings per share               
Net income per share available for common stockholders  $458,713    3,729,053,805   $0.00 
                
Effect of dilutive securities               
Convertible debt   163,565    547,490,575      
                
Diluted earnings per share               
Net income per share available for common stockholders  $622,278    4,276,544,380   $0.00 

 

For the three months ended September 30, 2021, the computation of basic and diluted earnings per share is calculated as follows:

 

      Number of  Per share
   Amount  shares  amount
          
Basic earnings per share               
Net income per share available for common stockholders  $1,525,766    2,875,702,002   $0.00 
                
Effect of dilutive securities               
Warrants   —      297,205,984      
Convertible debt   123,266    823,112,567      
                
Diluted earnings per share               
Net income per share available for common stockholders  $1,649,032    3,996,020,553   $0.00 

 

For the nine months ended September 30, 2022, the computation of basic and diluted earnings per share is calculated as follows:

 

      Number of  Per share
   Amount  shares  amount
          
Basic earnings per share               
Net income per share available for common stockholders  $41,135    3,693,636,223   $0.00 
                
Effect of dilutive securities               
Convertible debt   230,724    547,490,575      
                
Diluted earnings per share               
Net income per share available for common stockholders  $271,859    4,244,126,798   $0.00 

 

For the nine months ended September 30, 2021, the following warrants and convertible securities were excluded from the computation of diluted net loss per share as the results would have been anti-dilutive.

 

   Nine months ended
September 30,
2021
    
Warrants to purchase shares of common stock   684,345,057 
Convertible notes (in shares)   1,056,854,401 
    1,741,199,458 
Schedule of Antidilutive Securities

 

   Nine months ended
September 30,
2021
    
Warrants to purchase shares of common stock   684,345,057 
Convertible notes (in shares)   1,056,854,401 
    1,741,199,458